by rss feed | Feb 11, 2026 | David Sinclair, ER-100, gene therapy, News Feeds, partial reprogramming, Reprogramming
The FDA has cleared a trial of ER-100 from Life Biosciences for eye rejuvenation. In the trial, ER-100 will deliver inducible expression of the three reprogramming factors. Oct-4, Sox-2, and Klf-4 are colloquially known together as OSK. This trial is an extension of...
